Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06291826
Tafamidis meglumin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 20 mg soft gelatin capsule | EXPERIMENTAL | - |
| 40 mg (20 mg*2) soft gelatin capsule | EXPERIMENTAL | - |
| Placebo | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tafamidis meglumin | DRUG | A single oral dose of 20 mg capsule |
| Placebo | DRUG | A single oral dose of matched placebo. |
Inclusion Criteria: * Healthy male or females. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Exclusion Criteria: * Pregnant or nursing females. * Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
Tafamidis meglumin is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is a transthyretin (TTR) stabilizer that has been studied in a Phase 1 clinical trial in healthy volunteers. Its specific therapeutic indication has not been disclosed.
Tafamidis meglumin targets transthyretin, also known as TTR. It belongs to the TTR stabilizer class, meaning it is designed to bind and stabilize the TTR protein. This mechanism is distinct from approaches that reduce TTR production.
Tafamidis meglumin is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer conducted the clinical development work for this asset, including the Phase 1 study of single doses in Japanese and Western subjects.
Tafamidis meglumin is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The only recorded trial for this asset is a completed Phase 1 study, and no active trials are currently listed.
Tafamidis meglumin has been studied in one completed Phase 1 trial, NCT01369836, titled Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects. The trial enrolled 21 healthy volunteers in the United States, was randomized, double-blind, and active-controlled.
Tafamidis meglumin is the meglumine salt form of tafamidis, and the two names refer to the same active substance. The Phase 1 trial NCT01369836 lists the drug as PF-06291826 (Tafamidis), confirming these names identify the same compound.